S-1/A: Polomar Health Services Faces Mounting Losses Amid Strategic Shift and Merger Plans

Polomar Health Services, a compounding pharmacy, reported significant losses and negative working capital as it transitions its business model and pursues a merger with Altanine Inc., which is expected to give Altanine shareholders 80% ownership of the combined entity.

Summary

• Polomar Health Services operates Polomar Specialty Pharmacy, a Florida-licensed retail and sterile compounding pharmacy, currently authorized to deliver compounded medications in 30 states.
• The company is transitioning its business model from local dermatological compounding to online fulfillment of GLP-1 agonists and erectile dysfunction drugs, and plans to launch SlimRx (weight loss platform) and PoloMeds (diabetes, men's health) in Q1 2026.
• Polomar Pharmacy has experienced significant losses from operations, with a net loss of $1,712,193 for the nine months ended September 30, 2025, compared to $622,544 for the same period in 2024.
• Revenues for Polomar decreased to $16,174 for the nine months ended September 30, 2025, from $37,954 in the prior year, primarily due to the business model transition.
• Operating expenses for Polomar increased by approximately 256% to $1,618,886 for the nine months ended September 30, 2025, driven by legal, accounting, consulting, and payroll costs.
• The company has a negative working capital of ($1,305,466) as of September 30, 2025, and insufficient cash to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• Polomar is pursuing a merger with Altanine Inc., where Altanine shareholders are expected to own approximately 80% of the combined company, and Altanine will be the accounting acquirer.
• The Altanine merger is subject to several conditions, including supermajority stockholder consent, regulatory approvals, Nasdaq listing approval, and Polomar effecting a reverse stock split to achieve a $10.00 per share price.
• Altanine Inc. is an early-stage specialty pharmaceutical company focused on innovative drug delivery mechanisms, with no revenue generated since its inception in December 2023.
• Altanine reported a net loss of $4,581,010 for the nine months ended September 30, 2025, and had an accumulated deficit of $7,821,705, also raising substantial doubt about its going concern ability.
• Both Polomar and Altanine rely heavily on related-party debt for funding, with Polomar having $994,385 in related party promissory notes as of September 30, 2025, and Altanine having a $2,169,501 line of credit due to a related party.
• Polomar has a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. for GLP-1 agonist prescriptions, expecting steady revenue growth from this customer.
• A Product Fulfillment and Distribution Agreement with ForHumanity, Inc. grants exclusivity to market Polomar's inhalable sildenafil and eletriptan, with a guaranteed payment of $750,000 ($200,000 received by Sep 30, 2025) and revenue targets for exclusivity extensions.
• The company licensed patent-pending intellectual property from Pinata Holdings, Inc. (now an Altanine subsidiary) for proprietary drug delivery, valued at $9,735,000, but patent protection has not yet been granted by the USPTO.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including significant and increasing net losses, negative working capital, and substantial doubt about its ability to continue as a going concern. While there are strategic initiatives and merger plans, the underlying financial performance is very weak, and the merger itself introduces significant dilution and execution risks. The reliance on related-party debt and lack of independent capital access further compounds the negative outlook.

Positives

• Polomar Pharmacy is licensed in 30 states and actively seeking authorization in additional U.S. states by the end of 2025 and early 2026, indicating potential for market expansion.
• The company secured a one-year non-exclusive pharmacy services agreement with CareValidate, Inc. for GLP-1 agonist prescriptions, with expected steady revenue growth.
• A Product Fulfillment and Distribution Agreement with ForHumanity, Inc. includes a guaranteed payment of $750,000 and provides exclusivity for marketing inhalable sildenafil and eletriptan, with potential for extensions based on revenue targets ($1.5 million in Q1 2026, $3 million in H1 2026).
• Polomar has resolved manufacturing delays due to unexpected supply chain issues for active pharmaceutical ingredients.
• The planned launch of SlimRx (weight loss platform) and PoloMeds (diabetes and men's health) in Q1 2026 could diversify product offerings and revenue streams.
• The company's pre-filled injection pen system for GLP-1 agonists is believed to offer a competitive advantage over competitors' manual syringe systems, potentially enhancing user experience.

Negatives

• Polomar Health Services has a history of significant net losses, reporting $1,712,193 for the nine months ended September 30, 2025, and $1,341,333 for the year ended December 31, 2024.
• The company has a negative working capital of ($1,305,466) as of September 30, 2025, and insufficient cash to fund operations for the next 12 months.
• Revenue declined to $16,174 for the nine months ended September 30, 2025, from $37,954 in the prior year, primarily due to a business model transition.
• Operating expenses increased substantially by approximately 256% for the nine months ended September 30, 2025, compared to the same period in 2024.
• Both Polomar and Altanine have received 'going concern' warnings from their auditors, indicating substantial doubt about their ability to continue operations.
• The company is heavily reliant on related-party short-term debt and other current liabilities, totaling over $1,116,857 as of October 29, 2025, which it may be unable to repay.
• Altanine Inc., the accounting acquirer in the planned merger, has not generated any revenue since its inception in December 2023 and reported a net loss of $4,581,010 for the nine months ended September 30, 2025.
• The intellectual property licensed from Pinata, which is central to Polomar's new product offerings, has not yet been granted patent protection by the USPTO.
• The company's common stock is currently quoted on the OTCID Basic Market, with a limited trading market and a closing bid price of $0.08 on December 5, 2025, making it subject to 'penny stock' rules.
• The planned merger with Altanine Inc. will result in substantial dilution for current Polomar shareholders, who are expected to own only approximately 20% of the combined entity.
• The company has identified internal control deficiencies that constitute material weaknesses, which could lead to material misstatements or fraud.
• Failure to timely file periodic reports with the SEC has resulted in the loss of timely-filer status and ineligibility to use Form S-3 for at least 12 months, limiting capital raising options.

Risks

• Uncertainty of profitability based upon a history of losses.
• Risks related to failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Risks related to operations and uncertainties related to the business plan and business strategy.
• Changes in economic conditions.
• Uncertainty with respect to intellectual property rights, protecting those rights, and claims of infringement of others' intellectual property.
• Competition from well-established and well-capitalized competitors.
• Cybersecurity concerns.
• The planned merger with Altanine may not be successfully consummated, or delays could materially and adversely affect expected synergies.
• Significant related party short-term debt and other current liabilities, which the company may be unable to repay.
• Viable markets for products may never develop, may take longer to develop than anticipated, or may not be sustainable.
• Failure to meet development and commercialization milestones.
• Inability to manage rapid growth effectively.
• Credit market volatility and illiquidity may affect the ability to raise capital.
• Substantial dependence on licensed patent and other proprietary rights, with risks of failing to protect them or being unsuccessful in litigation.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information.
• A significant portion of the business may infringe on existing patents, leading to expensive and time-consuming litigation.
• Limited trading market for common stock, making it difficult to liquidate investments.
• No assurance that common stock will become listed on a securities exchange.
• Volatility in the market price and trading volume of common stock.
• Dilution of interest if additional shares of common stock are issued.
• Common stock is subject to penny stock rules of the SEC, making transactions cumbersome.
• Intention to issue more shares to raise capital will result in substantial dilution.
• Anti-takeover provisions in charter and bylaws may prevent or frustrate attempts by stockholders to change management.
• No intention to pay cash dividends in the foreseeable future.
• Increased costs and demands upon management as a result of being a public company.
• Failure to establish and maintain an effective system of internal controls, including identified material weaknesses.
• Failure to timely file periodic reports with the SEC may impact ability to utilize Form S-3 and subject to additional SEC review.
• Sales of restricted shares by selling stockholders could cause the market price of common stock to drop significantly.
• Lack of research or unfavorable reports from securities or industry analysts could cause stock price and trading volume to decline.
• Largest shareholder and its affiliates have substantial control over the company and its policies, which might not be in other shareholders' interests.
• Sale of common stock by selling stockholders could encourage short sales by third parties, contributing to further price decline.

Future Outlook

Polomar Health Services expects steady revenue growth from its CareValidate agreement and plans to launch its SlimRx and PoloMeds online platforms in early Q1 2026. The company anticipates increased research and development expenses as it advances product candidates through clinical trials and seeks regulatory approvals. Management plans to raise additional capital upon the closing of the Altanine Merger transaction and invest working capital in pharmacy operations and other business opportunities. However, there is no guarantee of sufficient capital or successful implementation of its business plan, and both Polomar and Altanine anticipate continued net losses for the foreseeable future.

Management Comments

• Polomar Pharmacy is actively seeking licenses and authorization in other states and expects to be able to provide prescription medications in additional U.S. states by the end of 2025 and early 2026.
• We expect steady revenue growth from the CareValidate customer.
• Polomar Pharmacy has experienced continuing delays in fully developing its compounded product formulations, manufacturing delays due to unexpected supply chain issues for imported active pharmaceutical ingredients and related products excipients, which have been satisfactorily resolved, and logistical challenges resulting from transitioning from a local fulfillment to national fulfillment business model.
• The Company has had insufficient access to capital to successfully implement its business plan.
• Any prescriptions issued via SlimRx will be compounded and fulfilled by Polomar Pharmacy.
• This wholesale part of the Company's business is expected to experience steady growth over the next twelve to eighteen months as the Company adds additional customers and fulfillment capacity.
• We believe our pre-filled injection pen system will provide an easier, better, and more comfortable user experience thereby providing us a potential marketing advantage.
• We expect that our pre-filled injection pens will be a more attractive delivery system for most patients, and we will be competitive on pricing.
• We believe that our integrated platform delivering telemedicine to patients and directly fulfilling prescription may provide an advantage and is likely to provide better margins on the products we sell.
• Management is currently in the process of looking for additional investors.

Industry Context

Polomar Health Services is operating in the highly competitive online prescription fulfillment marketplace, particularly for GLP-1 agonist weight loss drugs and erectile dysfunction formulations. Industry leaders like Hims/Hers and Ro currently control significant market share. Polomar aims to differentiate itself through its pre-filled injection pen system, which it believes offers a better user experience compared to competitors' manual syringe systems. The company's integrated platform, combining telemedicine and direct fulfillment, is also seen as a potential advantage for better margins. Direct competition includes companies like Levity Healthcare, Inc. and ZipHealth, Inc., which also offer compounding services and weight loss drugs, but Polomar believes its delivery system provides a competitive edge. The company's reliance on compounding pharmacies for FDA-unapproved formulations places it in a specific regulatory niche within the broader pharmaceutical and telehealth industries.

Comparison to Industry Standards

• Polomar's pre-filled injection pen system for GLP-1 agonists is positioned as a competitive advantage against industry leaders like Hims/Hers and Ro, which currently dispense GLP-1 drugs (semaglutide and tirzepatide) via traditional drug vials and manual syringes.
• Eli Lilly and Company, manufacturer of Mounjaro and Zepbound (Tirzepatide), offers direct-to-consumer sales through Lilly Direct at discounted prices ($399-$549/month), but their delivery system also requires manual measurement and filling of syringes, which Polomar believes its pre-filled pens will surpass in attractiveness.
• Hims/Hers and Ro are noted to sub-contract prescription fulfillment to other licensed compounding pharmacies, whereas Polomar aims for an integrated platform delivering telemedicine and directly fulfilling prescriptions, potentially leading to better margins.
• Levity Healthcare, Inc. and ZipHealth, Inc. offer similar compounding services and weight loss drugs, but their injectable medications are delivered in sterile bottles with syringes for manual filling, which Polomar believes its pre-filled injector pen system will be more attractive than.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending material legal proceeding.
• The company is not aware of any pending legal proceeding to which any officers, directors, or beneficial holders of 5% or more of voting securities are adverse to the company or have a material interest adverse to the company.

Related Party Transactions

• Polomar borrowed an aggregate of $1,138,570 from related parties (Reprise Management, Inc. and CWR 1, LLC) for operating expenses during the fiscal year ended December 31, 2024.
• As of September 30, 2025, the outstanding principal amount of the Reprise Note was $686,403.74 plus accrued interest of $18,815. Reprise is an affiliate of Daniel Gordon and GLD Partners, LP.
• On June 30, 2025, Reprise exchanged $300,000 of the Reprise Note for 60 shares of Polomar's Series A Convertible Preferred Stock.
• As of September 30, 2025, Polomar had received draws of $172,136.16 plus accrued interest of $2,152 under the CWR Note II. CWR is an affiliate of the company, and Daniel Gordon controls approximately 42% of Polomar's voting stock.
• On July 2, 2025, CWR exchanged the CWR Note for 90 shares of Polomar's Series A Convertible Stock.
• Polomar entered into the Profesco Note with Profesco Holdings, LLC, an entity managed by Terrence M. Tierney (CEO, President, Secretary, and Director). As of September 30, 2025, Polomar received draws of $114,878.36 under this note.
• On November 17, 2025, the Profesco Note was amended to increase the principal amount by $100,000 to $200,000, subject to a 3% origination fee and increased interest rates (15% initially, 18% after January 1, 2026).
• Pinata Holdings, Inc., from which Polomar licensed intellectual property, is an affiliate of CWR.
• Altanine Inc. borrows money under a loan agreement with GLD Sponsor Member II, LLC, an affiliate of Altanine's founder, Daniel Gordon. As of September 30, 2025, $2,169,501 was outstanding under this line of credit.
• Altanine issued a common stock purchase warrant to GLD on April 9, 2024, for the right to purchase up to 7,500,000 shares of common stock.
• On June 20, 2025, Altanine issued 40 shares of Series A Convertible Preferred Stock to GLD in exchange for a $1,000,000 pay down of its outstanding loan balance.

Stakeholder Impact

• Shareholders: Significant dilution is expected from the Altanine merger (current Polomar shareholders to own ~20% of combined entity) and future capital raises. The limited trading market and penny stock status may hinder liquidity and investment value. The substantial control by CWR and Daniel Gordon may not align with all shareholders' interests.
• Employees: The company's ability to retain and attract highly capable management and operating personnel is crucial for success, with stock incentive plans and employment agreements used as measures. Management changes post-merger will affect executive roles.
• Customers: The transition to online fulfillment of GLP-1 agonists and erectile dysfunction drugs, along with planned platform launches (SlimRx, PoloMeds), aims to expand customer reach and product offerings. Delays in product development and supply chain issues could impact customer satisfaction.
• Suppliers: Manufacturing delays due to supply chain issues for imported active pharmaceutical ingredients have been resolved, but reliance on foreign goods and potential tariffs remain a risk.
• Creditors: The company's significant related-party short-term debt and ongoing losses raise concerns about its ability to repay indebtedness, potentially increasing financial risk for lenders.

Next Steps

• Polomar Pharmacy expects to provide prescription medications in additional U.S. states by the end of 2025 and early 2026.
• Polomar plans to launch SlimRx (weight loss focused online platform) in early 2026.
• Polomar expects to launch PoloMeds (diabetes and men's health medications platform) during the first quarter of 2026.
• Polomar will further amend its SlimRx trademark application upon the launch of SlimRx.
• The company expects steady revenue growth from its CareValidate agreement over the next twelve to eighteen months.
• The Altanine Merger is pending, subject to conditions including supermajority stockholder consent, regulatory approvals, Nasdaq listing approval, and Polomar effecting a reverse stock split to achieve a $10.00 per share price.
• The combined company's Board will appoint George Hornig as Chairman and Charles Andres, Jr. as CEO, with Terrence M. Tierney becoming Executive Vice President and Chief Administrative Officer.
• Polomar is required to use its best efforts to enter into an Equity Credit Line in a minimum amount of $25 million.
• Polomar expects to incur increased costs and demands upon management as a result of being a public company.
• Management plans to raise additional capital and invest working capital resources in pharmacy operations and other potential business opportunities.

Key Dates

Recommendation

Polomar Health Services presents an extremely high-risk investment profile. The company has a history of substantial and increasing net losses, deeply negative working capital, and explicit 'going concern' warnings from its auditors, indicating severe financial instability and an inability to sustain operations without significant external funding. The proposed merger with Altanine Inc., itself an early-stage company with no revenue and significant losses, does not alleviate these concerns; instead, it introduces substantial dilution for existing Polomar shareholders (expected to own only 20% of the combined entity) and adds another layer of integration and execution risk. The heavy reliance on related-party debt, the lack of patent protection for key intellectual property, and the company's penny stock status further underscore the precarious position. While strategic shifts and new product launches are planned, the company's fundamental financial health is critically weak, making it a 'strong sell' for any seasoned investor or institution.

Keywords

Compounding Pharmacy, GLP-1 Agonists, Erectile Dysfunction, Telehealth, Weight Loss Medications, Semaglutide, Tirzepatide, Sildenafil, Pharmaceutical Delivery, Intellectual Property Licensing, SEC S-1/A Filing, Reverse Merger, Going Concern, Related Party Transactions, OTC Markets, Nasdaq Listing, Biotechnology, Specialty Pharma